---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-075997"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:41:52.546537+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cellectar stockholders approve 1.1M share increase to stock plan, re-elect directors

## Summary
- Stockholders approved 1,100,000-share increase to 2021 Stock Incentive Plan (3,025,557 for, 389,584 against).
- Class III directors Stefan D. Loren, Ph.D. and Douglas J. Swirsky re-elected to three-year terms.
- Ratification of Baker Tilly US, LLP as independent auditor for FY2023 approved (5,283,070 for, 54,947 against).
- Non-binding advisory vote on executive compensation approved (3,100,012 for, 311,122 against).

## SEC filing metadata
- accession: 0001104659-23-075997
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/tm2319838d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-075997
- JSON: https://secwatch.observer/filing/0001104659-23-075997.json
- Plain text: https://secwatch.observer/filing/0001104659-23-075997.txt

## Key facts
- Shareholder Votes
  Cellectar Biosciences, Inc. shareholders approved Approval of an Increase in Shares Available under the 2021 Stock Incentive Plan by 1,100,000 Shares at the 2023-06-23 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal No. 2 – Approval of an Increase in Shares Available under the 2021 Stock Incentive Plan by 1,100,000 Shares The Company requested approval of an increase in the number of shares of common stock available for issuance under the 2021 Stock Incentive Plan by 1,100,000 shares. The stockholders approved the increase . The vote was as follows: For Against Abstain Broker Non-Votes 3,025,557 389,584 42,978 1,929,917
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm
- Shareholder Votes
  Cellectar Biosciences, Inc. shareholders approved Approval of Executive Compensation at the 2023-06-23 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal No. 4 – Approval of Executive Compensation The Company requested approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The stockholders approved the compensation of the named executive officers. The vote was as follows: For Against Abstain Broker Non-Votes 3,100,012 311,122 46,985 1,929,917
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm
- Shareholder Votes
  Cellectar Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal No. 3 – Ratification of Appointment of Independent Registered Public Accounting Firm The Company requested ratification of the appointment by the Audit Committee of the Board of Directors of Baker Tilly US, LLP to be the Company’s independent registered public accounting firm for fiscal year 2023. The stockholders ratified the appointment. The vote was as follows: For Against Abstain 5,283,070 54,947 50,019
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm
- Shareholder Votes
  Cellectar Biosciences, Inc. shareholders approved Election of Class III Directors at the 2023-06-23 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal No.1 – Election of Directors Class III directors, Stefan D. Loren, Ph.D. and Douglas J. Swirsky, were nominated and elected to serve three-year terms. The vote was as follows: Nominee For Withheld Broker Non-Votes Stefan D. Loren, Ph.D. 3,046,236 411,883 1,929,917 Douglas J. Swirsky 3,298,548 159,571 1,929,917
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.